Emtricitabine / tenofovir alafenamide fumarate (Descovy) AWMSG Secretariat Assessment Report Emtricitabine/tenofovir alafenamide (as fumarate) (Descovy®) 200 mg/25 mg film-coated tablets Reference number: 2566 Full submission This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) The Routledge Academic Centre University Hospital Llandough Penlan Road Llandough Vale of Glamorgan CF64 2XX awttc@wales.nhs.uk 029 218 26900 This report should be cited as: All Wales Therapeutics & Toxicology Centre. AWMSG Secretariat Assessment Report. Emtricitabine/tenofovir alafenamide (as fumarate) (Descovy®) 200 mg/25 mg film-coated tablets. Reference number: 2566. June 2023
Emtricitabine/Tenofovir disoproxil Krka d.d. Emtricitabine/Tenofovir disoproxil Krka | European Medicines Agency (EMA)Skip to main contentSearchMain navigation * Medicines * Find medicine * Therapeutic areas: latest updates * Download medicine data * What we publish on medicines and when * Medicines under evaluation * National registers * Human regulatory * Overview * Research and development of EMA * Careers * Procurement * Glossaries * About this website * Data protection and privacy * Contacts 1. Home 2. Medicines 3. Emtricitabine/Tenofovir disoproxil Krka Emtricitabine/Tenofovir disoproxil KrkaRSSAuthorisedThis medicine is authorised for use in the European Union emtricitabine / tenofovir disoproxilMedicineHumanAuthorised Page contents * Overview * Product information * Product details
Doravirine, Lamivudine and Tenofovir disoproxil fumarate (delstrigo) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review
Emtricitabine, Bictegravir, Tenofovir alafenamide, Hemifumarate - Biktarvy Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information on drugs and health
Tenofovir Disoproxil Fumarate (Apo-Tenofovir) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical
Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 2 to I 7 of the dossier assessment Elvitegravir/Cobicistat/Emtricitabin/ Tenofoviralafenamid (HIV-1-Infektion [Kinder ≥ 2 bis < 6 Jahre und ≥ 14 kg Körpergewicht]) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (HIV-1 infection [children ≥ 2 to < 6 years and with a body weight of ≥ 14 kg]) – Benefit assessment according to §35a SGB V1 EXTRACT Project: A22-116 Version: 1.0
Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) ' Benefit assessment according to ' 35a SGB V 1 Translation of Sections I 1 to I 6 of the dossier assessment Bictegravir/Emtricitabin/Tenofoviralafenamid (HIV-Infektion bei Kindern und Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection in children and adolescents) Benefit assessment according to §35a SGB V1 EXTRACT Project: A22-134 Version: 1.0 Status: 24 March 2023 Extract of dossier assessment A22-134
Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) - human immunodeficiency virus-1 (HIV-1) Published 13 January 2025 Statement of advice SMC2760 bictegravir / emtricitabine / tenofovir alafenamide 30 mg / 120 mg / 15 mg film-coated tablet (Biktarvy®) Gilead Sciences Ltd 06 December 2024 ADVICE: in the absence of a submission from the holder of the marketing authorisation bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy®) is not recommended for use within NHSScotland. Indication under review: treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25 kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. The holder
Emtricitabine , Darunavir ethanolate, Cobicistat, Tenofovir alafenamide hemifumarate - (Symtuza) Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information
Doravirine/lamivudine/tenofovir disoproxil (HIV infection) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 5 of the dossier assessment Doravirin/Lamivudin/Tenofovirdisoproxilfumarat (HIV-Infektion bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2022). Please note : This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-49 Doravirine/lamivudine/tenofovir disoproxil fumarate (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A22-49 Version 1.0 DOR/3TC
Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Receiving Oncology Drug Treatment Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Receiving Oncology Drug TreatmentCopied to clipboardAntiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Receiving Oncology Drug Treatment( Last Updated : September 9, 2022)Project Line:Health Technology ReviewProject Sub Line:Rapid ReviewProject Number:RC1448-000Effective finish date:August 25, 2022DetailsQuestionWhat is the clinical effectiveness of antiviral prophylaxis
emtricitabine / tenofovir disoproxil Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu * Home * COVID-19Specific
doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu
Higher Relapse Rate in HBeAg-negative Patients After Cessation of Tenofovir Alafenamide Compared to Entecavir or Tenofovir Disoproxil Fumarate. There is limited information comparing the off-therapy relapse rates of patients discontinued tenofovir alafenamide (TAF) to those stopping entecavir or tenofovir disoproxil fumarate (TDF). A total of 805 HBeAg-negative patients without cirrhosis
Measurements of tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots of people receiving pre-exposure prophylaxis for HIV with co-formulated tenofovir disoproxil fumarate and emtricitabine. Data regarding the concentrations of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) in the Asian population receiving pre-exposure prophylaxis (PrEP ) for HIV with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) (TDF/FTC) are limited, and the associations between the frequency of TDF/FTC administration and drug concentration among people receiving on-demand PrEP remain unclear. Fifty-seven participants receiving daily TDF/FTC and 113 participants receiving on-demand TDF/FTC were enrolled in this study. The concentrations of TFV-DP and FTC
Tenofovir alafenamide for treating chronic hepatitis B infection ACE Technology Guidances A Singapore Government Agency Website SEARCH Who We Are Organisational Structure Advisory Committees Committees We Serve Careers at ACE Healthcare Professionals ACE Clinical Guidances (ACGs) ACE CUES ACE Technology Guidances ACE Horizon Scanning Patients & Community Asthma Resources Plain English Summaries listing tenofovir alafenamide (TAF) on the Medication Assistance Fund (MAF) for treating chronic hepatitis B infection, due to unfavourable cost-effectiveness compared with tenofovir disoproxil fumarate (TDF) at the price proposed by the manufacturer. Tenofovir alafenamide for treating chronic hepatitis B infection (18 Jan 2021) 21 Feb 2022 Agency for Care Effectiveness (ACE)Who We
Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) - HIV Published 8 March 2021 1 Product update SMC2333 doravirine/lamivudine/tenofovir disoproxil fumarate 100mg/300mg/245mg film-coated tablets (Delstrigo®) Merck Sharp & Dohme (UK) Limited 5 February 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) is accepted for use within NHSScotland. Indication under review: for the treatment of adults infected with HIV-1 without past or present
Bictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV Skip to navigationSkip to contentA-Z MedicinesFAQSubscribeSearchSearchSearch medicinePBS MEDICINE SEARCHHomePBS InformationBrowse the PBSFor Health ProfessionalsFor IndustryNewsPublications & DownloadsContactsHome/ Industry/ Listing/ Participants/ Public Release Docs/ 2021 10/ Bictegravir Emtricitabine Tenofovir Alafenamide And DolutegrBictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV, October 2021Page last updated: 24 March 2022Drug utilisation sub-committee (DUSC)October 2021AbstractPurposeTo review the predicted versus actual utilisation of bictegravir+emtricitabine+tenofovir alafenamide (Biktarvy) and dolutegravir+rilpivirine (Juluca) in the first 24 months of R/PBS
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. BICSTaR (BICtegravir Single Tablet Regimen) is an ongoing, observational cohort study assessing the virologic effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF
Urine tenofovir adherence testing: Perspectives of recently diagnosed South African adolescents and young adults with HIV accessing care via mobile HIV clinics. Adolescents and young adults (AYA) living with HIV face several challenges to engaging in HIV care, which can impact adherence to antiretroviral therapy (ART). Point-of-care (POC) diagnostics that detect tenofovir in urine may be a useful tool to support ART adherence, but perspectives from AYA in South Africa have not been explored. We conducted in-depth interviews (IDIs) among young people (age 18-24) newly diagnosed with HIV in Cape Town, and a focus group discussion (FGD) with HIV care providers to understand their perspectives regarding the use of POC urine tenofovir testing to support ART adherence. Transcripts were